BSH 2018 | The role of TP53 in CLL
Christopher Fox
• 14 Apr 2018
In this interview, Christopher Fox, MBChB(Hons), MRCP, FRCPath, of Nottingham University Hospitals NHS Trust, Nottingham, UK, provides an overview of the role of TP53 mutations in both the laboratory and clinical setting. TP53 sequencing, along with FISH, can be used to provide insight into a patient’s prognosis and possibly alter treatment regiments. However, this is based upon the type of techniques employed and whether the clones are reliably mutated. This video was recorded the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK.
